Image pharmaphorum Editor Views & Analysis What CX Tech Innovations Options Are Ripe for Consideration? Innovation is often driven by frustration. Views & Analysis Life sciences must become cloud-first to seize the science o... If the power of the life sciences industry to innovate and collaborate were ever in doubt, the speed at which vaccines for COVID-19 were discovered, developed, trialled, approved and manufa Views & Analysis Why pharma isn’t yet achieving digital excellence, and how i... Nearly 70% of HCPs are now digital natives, with no interest in going back to pre-COVID sales engagement methods. Views & Analysis LEO Pharma’s new R&D lead on driving agility in drug develop... After 27 years at Bayer, Jörg Möller has moved to LEO Pharma as the company’s EVP, global research and development. Load more results
Views & Analysis What CX Tech Innovations Options Are Ripe for Consideration? Innovation is often driven by frustration.
Views & Analysis Life sciences must become cloud-first to seize the science o... If the power of the life sciences industry to innovate and collaborate were ever in doubt, the speed at which vaccines for COVID-19 were discovered, developed, trialled, approved and manufa
Views & Analysis Why pharma isn’t yet achieving digital excellence, and how i... Nearly 70% of HCPs are now digital natives, with no interest in going back to pre-COVID sales engagement methods.
Views & Analysis LEO Pharma’s new R&D lead on driving agility in drug develop... After 27 years at Bayer, Jörg Möller has moved to LEO Pharma as the company’s EVP, global research and development.
News Sanofi's bispecific lunsekimig has mixed readouts in phase 2 Sanofi's IL-13 and TSLP-targeting bispecific lunsekimig wins two, loses one, in readouts from its midstage clinical trials programme.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
